Executive Summary
Generated July 30, 2026
Neurotechnology
Synchron
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
1
Chokepoint Score
1 other entity structurally depend on this one
Headquarters
Brooklyn, New York, USA
Website
Employees
150 (2026, approximate)
Founded
2012
Listing
private
Overview
Developer of the Stentrode, a brain-computer interface delivered through blood vessels without open-skull surgery, targeting patients with paralysis. Synchron raised a $200 million Series D in November 2025 (bringing total funding to $345 million) to fund a 2026 pivotal clinical trial -- the study required before Synchron can seek the first FDA premarket approval (PMA) for an implantable BCI -- and is developing a next-generation, higher-channel-count transcatheter interface at a new San Diego engineering hub.
Strategic Connections
- Brain-Computer Interfaces: Synchron develops the Stentrode, a transcatheter (blood-vessel-delivered) brain-computer interface.
- Neuralink: Synchron competes with Neuralink and Precision Neuroscience toward the first FDA-approved implantable brain-computer interface, differentiating on its less invasive, catheter-based delivery.
- Precision Neuroscience: Synchron competes with Precision Neuroscience in the race to reach BCI regulatory and commercial milestones.
Strategic Risks
- Pivotal trial outcomes and FDA PMA timeline remain uncertain
- Competes against better-capitalized Neuralink for talent and trial sites
Future Outlook
- 2026 pivotal trial results seen as gating event for first FDA-approved implantable BCI
- Developing next-generation high-channel-count interface for broader applications
Sources
2 sources, 66% average source confidence — full citations in the Full Analyst Report.
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Executive Summary — switch to the Full Analyst Report.